← k3vl4r
Log inGet started →

PHAT (Phathom Pharmaceuticals Inc) Price Forecast

AI-generated price forecast for Phathom Pharmaceuticals Inc (PHAT) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

The desk streams live daily· see the schedule →

As of October 2026: K3vl4r's calibrated AI forecast currently reads PHAT as 1/1 bearish across its horizons (0 of 1 timeframes pointing up), with a last price of 7.25. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP

Last price

7.25

AI outlook

1/1 bearish

Timeframes up

0 / 1

Share𝕏PostTelegram

PHAT forecast by horizon

HorizonDirectionCalibrated move (end of horizon)
1-hour——
4-hour——
Daily~4 weeks out▼ Down-36.84%
WeeklyNot enough track record yet—

Calibrated: each horizon's forecast is weighted by how often the model has called PHAT's direction correctly over the last 30 days, and reversed where it has been wrong more often than right. A horizon votes only once it has enough resolved forecasts.

Latest PHAT news

From the market-news feed the forecasts are read against.

  • Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting · Yahoo · Oct 8
  • Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD · Yahoo · Sep 29
  • Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD · Benzinga · Sep 29
  • Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year Low - What's Next? · ldr:marketbeat.com · Sep 11

🔒

See the full PHAT forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

PHAT forecast — frequently asked

Will PHAT go up?

K3vl4r's calibrated AI forecast currently reads PHAT as 1/1 bearish — 0 of 1 forecast horizons point up, so the overall read is leaning to the downside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the PHAT price prediction for 2026?

K3vl4r's model projects PHAT toward $4.58 over the next ~4 weeks, a -36.8% move from $7.25. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

EWTXSLSSIGAACHVQTRXLTRNXERSCLDXSNDXDRMACODXCAPRCNMDCOCP

Will PHAT reach…?

Will PHAT reach $10.00?Will PHAT reach $20.00?Will PHAT reach $25.00?Will PHAT reach $50.00?

Or see the full PHAT price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare PHAT

PHAT vs EWTXPHAT vs SLSPHAT vs SIGAPHAT vs ACHVPHAT vs QTRXPHAT vs LTRN

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

StreamWatch on Kick·Watch on YouTube
k3vl4rTop PicksTrack recordChart indicatorsToday's outlookStream scheduleBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsPricingX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch the desk stream live on Kick or YouTube. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.